GT Biopharma (DB:OXIA) - Stock Price, News & Analysis

OXIA Stock Overview

A clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

About the company

OXIA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 55.4% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€4M)

Shareholders have been diluted in the past year

+ 1 more risk

GT Biopharma, Inc. Competitors

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.0m

Medigene

XTRA:MDG1

€31.0m

4SC

DB:VSC

€56.1m

Price History & Performance

Summary of all time highs, changes and price drops for GT Biopharma
Historical stock prices
Current Share Price	US$4.77
52 Week High	US$10.74
52 Week Low	US$4.77
Beta	0.57
11 Month Change	0%
3 Month Change	-9.66%
1 Year Change	-48.71%
33 Year Change	-98.53%
5 Year Change	n/a
Change since IPO	-96.48%

Recent updates

Shareholder Returns

	OXIA	DE Biotechs	DE Market
7D	0%	2.2%	-1.9%
1Y	-48.7%	-9.6%	12.3%

Return vs Industry: OXIA underperformed the German Biotechs industry which returned -21.6% over the past year.

Return vs Market: OXIA underperformed the German Market which returned 2.2% over the past year.

Price Volatility

Is OXIA's price volatile compared to industry and market?
OXIA volatility
OXIA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: OXIA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine OXIA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1965	2	Michael Breen	www.gtbiopharma.com

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma, Inc. Fundamentals Summary

How do GT Biopharma's earnings and revenue compare to its market cap?
OXIA fundamental statistics
Market cap	€3.89m
Earnings (TTM)	-€7.13m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is OXIA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OXIA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$7.60m
Earnings	-US$7.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-5.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did OXIA perform over the long term?

See historical performance and comparison

GT Biopharma DB:OXIA Stock Report